Global Market for Cell and Gene Therapy

Apr 2024| BIO225B| BCC Publishing

Report Highlights

The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028. 

Report Includes

  • 23 data tables and 54 additional tables
  • An overview of the global market for cell and gene therapy
  • Analysis of global market trends, featuring historical revenue data for 2020, 2021, and 2022, estimated figures for 2023, forecasts for 2028, and projections of compound annual growth rates (CAGRs) through 2028
  • Evaluation of the current market’s size and revenue growth prospects specific to cell and gene therapy, along with a market share analysis by therapy type, product, application, and geographic region
  • An update on recent advances in vector biology, drug delivery technology and gene editing technologies such as CRISPR
  • Coverage of novel therapeutic products and promising new technologies still in the development and testing stage, with as assessment of the probability that they will be commercialized successfully in the next five years
  • Discussion on recent approvals, developments, emerging technologies, ESG, and an investment outlook
  • Profiles of leading market participants, including Novartis, Vericel Corp., Gilead Sciences Inc., Pharmicell Co. Ltd., and Bristol-Myers Squibb Co.

Report Scope

The scope of this study encompasses an investigation of the cell and gene therapy market, which includes a detailed analysis of the market's drivers, challenges and opportunities. The report also covers market projections to 2028 and market shares of key companies. The report includes the company profiles of the key players with information about their business segments, financials, product portfolios and recent developments. The report also provides information on emerging technologies and the outlook for the investment climate.

Frequently Asked Questions (FAQs)

The global market for cell and gene therapy reached $5.8 billion in 2022. The total CGT market is estimated to reach $23.3 billion through 2028, growing at a CAGR of 26.4% during the forecast period.
  • Increasing prevalence of chronic diseases
  • Increasing investment in CGT research
  • Increasing CGT approvals
  • Increasing clinical and commercial manufacturing capacity
The global market is segmented based on therapy type, product type, application and region. Based on therapy type, the market is categorized into cell therapy, gene-modified cell therapy and gene therapy. Based on product type, the market is segmented into Zolgesma, Yescarta, Kymriah, Abecma, Maci, Tecartus, Epicel and others. Based on application, the market for cell and gene therapy is segmented into rare diseases, oncology, ophthalmology, and others (includes neurology, cardiovascular, blood disorders etc).
Gene Therapy will dominate the market by the end of 2028.
North America holds the highest share in the market.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2023-2028
Base year market size $5.8 billion
Market size forecast $23.3 billion
Growth rate CAGR of 26.4% for the forecast period of 2023-2028
Units considered $ Millions
Segments covered Therapy Type, Product Type, Application, and Region
Regions covered North America, Europe, Asia-Pacific, and Rest of the World
Countries covered U.S., Mexico, Canada, Germany, U.K., France, China, Japan, Australia
Key Market Drivers
  • Increasing prevalence of chronic diseases.
  • Growing investments in cell and gene therapy research.
  • Expanding manufacturing capacity.
  • Increasing numbers of cell and gene therapy approvals
Companies studied
  • MALLINCKRODT PLC
  • NOVARTIS AG
  • ORCHARD THERAPEUTICS PLC.
  • PHARMICELL CO. LTD.
  • UNIQURE N.V.
  • VERICEL CORP.
  • AMGEN INC.
  • BLUEBIRD BIO INC.
  • BRISTOL-MYERS SQUIBB CO.
  • DENDREON PHARMACEUTICALS LLC.
  • FERRING PHARMACEUTICALS
  • GILEAD SCIENCES INC.
  • IOVANCE BIOTHERAPEUTICS INC.
  • JOHNSON & JOHNSON SERVICES INC.
  • KRYSTAL BIOTECH INC.

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Global Market for Cell and Gene Therapy130Free
Chapter- 1: Executive Summary4Free
Chapter- 2: Market Overview 11Free
Chapter- 3: Market Dynamics 11Free
Chapter- 4: Market Segmentation Analysis51Free
Chapter- 5: Competitive Intelligence14Free
Chapter- 6: Sustainability: An ESG Perspective 4Free
Chapter- 7: Appendix35Free
Published - Feb-2022| Analyst - BCC Publishing| Code - BIO225A

Report Highlights

The global market for cell and gene therapy should grow from $4.1 billion in 2021 to $17.4 billion by 2026 with a compound annual growth rate (CAGR) of 33.6% for the period of 2021-2026.

Report Includes

  • 20 data tables and 25 additional tables
  • An overview of the global market for cell and gene therapy (CGT) products and their applications
  • Analyses of the global market trends, with historic data from 2019-2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
  • Evaluation and forecast the overall market size for cell and gene therapy, forecasted growth trends, and corresponding market share analysis by product type, therapy type, application, and region
  • Highlights of the upcoming market potential of cell and gene therapy products and areas of focus to forecast this market into various segments and sub-segments
  • In-depth information (facts and figures) concerning market drivers, market deterrents and other demographic and economic factors that will drive future demand for this market
  • Identification of novel therapeutic products and promising new technologies still in the development and testing stage, and assess the probability that they will be commercialized successfully in the next five years
  • Review of emerging companies and the leading competitors in the prevailing cell and gene therapy market, and their global company share analysis
  • Impact of COVID-19 pandemic on cell and gene therapy market and related biotech industry
  • Review of pipeline analysis and the total number of CGT clinical trials by clinical trial phase, disease indication, and geography
  • Descriptive company profiles of the major global players, including Novartis, Orchard Therapeutics plc, Pharmicell Co. Ltd., Sibiono Genetech Co. Ltd., Vericel Corp. and Bristol-Myers Squibb Co.
Global Market for Cell and Gene Therapy

Single User License: $5500

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS